{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:55:45Z","timestamp":1778626545857,"version":"3.51.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Korean Association for the Study of the Liver and the Korean Liver Foundation","award":["KASLKLF2022-05"],"award-info":[{"award-number":["KASLKLF2022-05"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea","award":["NRF-2022R1A2C3008956 and NRF-2021R1A6A1A03040260"],"award-info":[{"award-number":["NRF-2022R1A2C3008956 and NRF-2021R1A6A1A03040260"]}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2022IT0013"],"award-info":[{"award-number":["2022IT0013"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asan Cancer Institute of Asan Medical Center","award":["Elimination of Cancer Project Fund"],"award-info":[{"award-number":["Elimination of Cancer Project Fund"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Few large-scale studies have investigated factors associated with the development of hepatocellular carcinoma (HCC) in patients with autoimmune hepatitis (AIH). This study aimed to determine the risk of HCC in AIH patients and associated risk factors, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD). We analyzed the claims data from the Korean National Health Insurance Service from 2007 to 2020. The study included 7,382 patients with AIH and a control group of 58,538 age- and sex-matched individuals, at a ratio of 1:8. We compared the incidence rates of HCC between these groups and investigated the risk factors of HCC. During a median follow-up of 5.9 years, 160 AIH patients were diagnosed with HCC, resulting in an incidence rate of 3.60 per 1,000 person-years. The matched controls exhibited an incidence rate of 0.48 per 1,000 person-years. After adjustment, AIH patients had a 4.85-fold heightened risk of HCC compared to the control group. Within the AIH cohort, the presence of coexisting MASLD further elevated the risk of HCC, along with other factors such as older age, male sex, and decompensated liver cirrhosis, as observed in a two-year landmark analysis. The presence of concurrent extrahepatic autoimmune diseases did not affect the prognosis, while glucocorticoid treatment was associated with a decreased risk of HCC. Patients with AIH had an increased risk of HCC compared to matched controls, particularly those with coexisting MASLD. In addition to appropriate medical treatment, proactive interventions and lifestyle modifications for concurrent MASLD are recommended for these patients.<\/jats:p>","DOI":"10.1371\/journal.pone.0325066","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:28:16Z","timestamp":1753205296000},"page":"e0325066","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of metabolic dysfunction-associated steatotic liver disease on hepatocellular carcinoma risk in autoimmune hepatitis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1878-0215","authenticated-orcid":true,"given":"Jihye","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-2970","authenticated-orcid":true,"given":"Ye-Jee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-6957","authenticated-orcid":true,"given":"Sehee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-1371","authenticated-orcid":true,"given":"Ju Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"2","key":"pone.0325066.ref001","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and Management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases","volume":"72","author":"CL Mack","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"pone.0325066.ref002","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0325066.ref003","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3350\/cmh.2023.0087","article-title":"KASL clinical practice guidelines for management of autoimmune hepatitis 2022","volume":"29","author":"Korean Association for the Study of the Liver (KASL)","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"pone.0325066.ref004","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jgh.14746","article-title":"Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population","volume":"34","author":"T Lv","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0325066.ref005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3350\/cmh.2020.0189","article-title":"Recent updates on the management of autoimmune hepatitis","volume":"27","author":"A Komori","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"pone.0325066.ref006","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"SI Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"5","key":"pone.0325066.ref007","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cancers13051023","article-title":"Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases","volume":"13","author":"EI Rigopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0325066.ref008","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2017.02.006","article-title":"Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"A Tansel","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0325066.ref009","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"ML Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"pone.0325066.ref010","doi-asserted-by":"crossref","first-page":"601710","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"D Suresh","year":"2020","journal-title":"Front Oncol"},{"key":"pone.0325066.ref011","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/JHC.S283840","article-title":"Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma","volume":"9","author":"NC Chavez-Tapia","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"pone.0325066.ref012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/JHC.S344559","article-title":"Hepatocellular carcinoma due to nonalcoholic fatty liver disease: current concepts and future challenges","volume":"9","author":"MI Ahmad","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"pone.0325066.ref013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/apt.16706","article-title":"Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver","volume":"55","author":"MN Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0325066.ref014","first-page":"97","volume-title":"National Health Insurance and Long-Term Care Insurance System in Republic of Korea","author":"National Health Insurance Service(NHIS)","year":"2023"},{"key":"pone.0325066.ref015","author":"National Heatlh Insurance Sharing Service(NHISS)","year":"2023"},{"key":"pone.0325066.ref016","volume-title":"Status of general health examination targets and number of examinees [Internet]","author":"Korean Statistical Information Service(KOSIS)","year":"2023"},{"key":"pone.0325066.ref017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"G Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"pone.0325066.ref018","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"pone.0325066.ref019","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cam4.1998","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment","volume":"8","author":"K Tarao","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"pone.0325066.ref020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s12072-021-10249-9","article-title":"Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"L-J Yan","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0325066.ref021","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/aje\/kwab119","article-title":"Cancer risk in patients with autoimmune hepatitis: a nationwide population-based cohort study with histopathology","volume":"191","author":"R Sharma","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pone.0325066.ref022","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14309\/ajg.0000000000001525","article-title":"Increased cancer risk in autoimmune hepatitis: a danish nationwide cohort study","volume":"117","author":"MD Jensen","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"pone.0325066.ref023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2023.09.010","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"80","author":"F Colapietro","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0325066.ref024","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"H Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"pone.0325066.ref025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.007","article-title":"Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model","volume":"69","author":"P M\u00fcller","year":"2016","journal-title":"J Autoimmun"},{"issue":"8","key":"pone.0325066.ref026","doi-asserted-by":"crossref","first-page":"100778","DOI":"10.1016\/j.jhepr.2023.100778","article-title":"Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease","volume":"5","author":"K Zachou","year":"2023","journal-title":"JHEP Rep"},{"issue":"3","key":"pone.0325066.ref027","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD","volume":"81","author":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0325066.ref028","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"pone.0325066.ref029","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","article-title":"Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis","volume":"103","author":"AJ Montano-Loza","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"pone.0325066.ref030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"DW Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"pone.0325066.ref031","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/me.2016-1029","article-title":"Glucocorticoids have opposing effects on liver fibrosis in hepatic stellate and immune cells","volume":"30","author":"KH Kim","year":"2016","journal-title":"Mol Endocrinol"},{"issue":"7","key":"pone.0325066.ref032","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/liv.15241","article-title":"Treatment and outcome of autoimmune hepatitis (AIH): audit of 28 UK centres","volume":"42","author":"V Gordon","year":"2022","journal-title":"Liver Int"},{"issue":"6","key":"pone.0325066.ref033","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"AW Lohse","year":"2020","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0325066.ref034","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/liv.15382","article-title":"Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality","volume":"42","author":"R Birn-Rydder","year":"2022","journal-title":"Liver Int"},{"issue":"3","key":"pone.0325066.ref035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/liv.13236","article-title":"Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes","volume":"37","author":"G-W Wong","year":"2017","journal-title":"Liver Int"},{"issue":"9","key":"pone.0325066.ref036","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","article-title":"External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study","volume":"11","author":"EM Koehler","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"pone.0325066.ref037","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ajg.2014.155","article-title":"Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis","volume":"109","author":"PJ Meffert","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"pone.0325066.ref038","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/j.1478-3231.2011.02580.x","article-title":"Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population","volume":"31","author":"JH Kim","year":"2011","journal-title":"Liver Int"},{"issue":"10","key":"pone.0325066.ref039","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/hepr.13935","article-title":"Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: impact of alcohol consumption and sex","volume":"53","author":"T Nomura","year":"2023","journal-title":"Hepatol Res"},{"key":"pone.0325066.ref040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: a comprehensive review","volume":"41","author":"R Liberal","year":"2013","journal-title":"J Autoimmun"},{"key":"pone.0325066.ref041","first-page":"644376","article-title":"Metabolomic signatures of autoimmune hepatitis in the development of cirrhosis","volume":"8","author":"S-S Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pone.0325066.ref042","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Liver European Association for the Study of the","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0325066.ref043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000341115","article-title":"Autoimmune hepatitis: new guidelines, new therapies","volume":"30","author":"CP Strassburg","year":"2012","journal-title":"Dig Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:28:22Z","timestamp":1753205302000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325066"}},"subtitle":[],"editor":[{"given":"Ashraf","family":"Elbahrawy","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325066","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}